Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilacidin - Innovation Pharmaceuticals

Drug Profile

Brilacidin - Innovation Pharmaceuticals

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Amides; Anti-inflammatories; Antibacterials; Guanidines; Peptidomimetics; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Stomatitis

Highest Development Phases

  • Phase II Skin and soft tissue infections; Stomatitis; Ulcerative proctitis
  • Preclinical Acne; Atopic dermatitis; Hidradenitis suppurativa; Inflammatory bowel diseases; Ulcerative colitis
  • No development reported Diabetic foot ulcer; Otitis; Wounds
  • Discontinued Intestinal infections; Ophthalmic infections

Most Recent Events

  • 25 Nov 2019 The US FDA waives Paediatric Investigation Plan for Stomatitis in patients with Head and neck cancer
  • 13 Nov 2019 Brilacidin is available for licensing for Stomatitis (Prevention) as of 13 Nov 2019. www.ipharminc.com
  • 03 Oct 2019 Innovation Pharmaceuticals plans a phase III trial for Stomatitis (In volunteers) in December 2019 (Topical, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top